OPTI Optimi Health Corp.
Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. The company also engages in farming, processing, and distribution of raw mushroom biomass, mushroom extracts, manufacturing of drug products, and mushroom supplements. It sells its products through Amazon marketplace and distributors/brokers, as well as online. Optimi Health Corp. was incorporated in 2020 and is based in Princeton, Canada.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Optimi Health (CNSX: OPTI)
›
Optimi Health (CNSX: OPTI) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.
The shares were at 2.600 CAD on 19 November 2026, down 76.9% over 52 weeks. Its 52-week range is 2.550 CAD to 12.60 CAD: the price is 79.4% below the high and 2.0% above the low.
Its market capitalisation is 14.89M CAD.
Optimi Health reports return on equity of -56.5% and revenue down 28.6% year over year.
It holds more cash than debt, a net cash position of 7.93M CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.